Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study).

Abstract

OBJECTIVE To investigate the efficacy and safety of the interleukin-6 receptor antibody tocilizumab in patients with Takayasu arteritis (TAK). METHODS Patients with TAK who had relapsed within the previous 12 weeks were induced into remission with oral glucocorticoid therapy. In this double-blind, placebo-controlled trial, patients were randomly assigned… (More)
DOI: 10.1136/annrheumdis-2017-211878

Topics

6 Figures and Tables

Cite this paper

@article{Nakaoka2017EfficacyAS, title={Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study).}, author={Yoshikazu Nakaoka and Mitsuaki Isobe and S. Takei and Yoshiya Tanaka and Tomonori Ishii and Shumpei Yokota and Akira Nomura and Seitaro Yoshida and Norihiro Nishimoto}, journal={Annals of the rheumatic diseases}, year={2017} }